HPVC2019-058 Pharmaceutical Products and IV Fluids
Current Contract
Description
Contract for the provision of a range of pharmaceutical products and intravenous fluids to Victorian Public Health Services.Additional Information
Update 1: 2 March 2021
HPVITS2019-058.003 – Pharmaceutical Products and IV Fluids Supplementary 003
Please note that this tender is now accessible via the HSV Procurement Portal
Market Engagement Date: 1 March 2021 – 19 March 2021
Announcement of outcome to suppliers: 13 May 2021*
Announcement of outcome to health services: 27 May 2021*
Contract Commencement Date: 10 June 2021*
*Please note all dates listed are indicative dates
Scope:
Subcategory number | Subcategory name |
517.01 |
Arsenic trioxide 10mg/10mL injection, ampoule/vial,10mL |
83001.01 |
Bevacizumab 100mg/4mL injection, ampoule/vial, 4mL |
83001.02 |
Bevacizumab 400mg/16mL injection, ampoule/vial, 16mL |
518.01 |
Bortezomib injection, ampoule/vial |
519.01 |
Cabazitaxel 60mg injection, ampoule/vial |
527.01 |
Carmustine 100mg injection, ampoule/vial |
520.01 |
Daptomycin 350mg injection, ampoule/vial |
520.02 |
Daptomycin 500mg injection, ampoule/vial |
521.01 |
Deferasirox 90mg tablet/capsule 30 |
521.02 |
Deferasirox 180mg tablet/capsule 30 |
521.03 |
Deferasirox 360mg tablet/capsule 30 |
522.01 |
Desflurane 1mL/1mL or 1g/1g Inhalation solution, bottle 250mL |
197.03 |
Furosemide (Frusemide) 20mg/2mL injection, ampoule/vial, 2mL |
523.01 |
Imatinib 100mg tablet/capsule 30 (GIST indication) |
523.02 |
Imatinib 100mg tablet/capsule 30 (non-GIST indication) |
523.03 |
Imatinib 400mg tablet/capsule 60 (GIST indication) |
523.04 |
Imatinib 400mg tablet/capsule 60 (non-GIST indication) |
524.01 |
Methylprednisolone (sodium succinate) 500mg injection, ampoule/vial |
524.02 |
Methylprednisolone (sodium succinate) 1g injection, ampoule/vial |
325.02 |
Moxifloxacin 400mg tablet/capsule 5 |
525.01 |
Oseltamivir 30mg capsule 10 |
525.02 |
Oseltamivir 45mg capsule 10 |
525.03 |
Oseltamivir 75mg capsule 10 |
526.01 |
Sodium nitroprusside 50mg/2mL injection, ampoule/vial, 2mL |
499.04 |
Vancomycin 500mg injection, ampoule/vial |
Since this tender has been released, please direct all correspondence through the HSV Procurement Portal. For any difficulties accessing the HSV Procurement Portal, please contact helpdesk@healthsharevic.org.au for assistance.
Update 2: 2 March 2021
HPVITS2019-058.010 – Pharmaceutical Products and IV Fluids Supplementary 010
Announcement of outcome to suppliers: 12 March 2021*
Announcement of outcome to health services: 23 March 2021*
Contract Commencement Date: 1 April 2021*
*Please note all dates listed are indicative dates
HSV has engaged directly with all suppliers with current ARTG registration for Rituximab intravenous.
Scope:
81001.02 RITUXIMAB 100 MG/10 ML INJECTION, AMPOULE/VIAL 10 ML
81001.03 RITUXIMAB 500 MG/50 ML INJECTION, AMPOULE/VIAL 50 ML.
Since this tender has been released, please direct all correspondence through the HSV Procurement Portal. For any difficulties accessing the HSV Procurement Portal, please contact helpdesk@healthsharevic.org.au for assistance.
Useful information:
1. To subscribe and receive contract update notifications, favourite this contract cabinet.
2. Review your account settings to ensure the notification frequency selected is adequate.
3. Information for Prospective Suppliers can be found on our website: https://www.hpv.org.au/tenders-and-contracts/information-for-prospective-suppliers/
Categories
Category 1 - Pharmaceutical ProductsCategory 50,000 - Intravenous Fluids
Category 60,000 - Parenteral Nutrition Solutions
Category 70,000 - Irrigating Solutions
Category 80,000 - Biopharmaceuticals
Category 90,000 – Therapeutic Group Approach